Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
January 10, 2023
-
REGULATORY MHLW Eyes April Proposal to Push Generic Industry Shake-Up: Asst. Vice Minister
January 6, 2023
-
BUSINESS Japan Likely to See Generic Listing for Azilva, Zytiga in 2023; Xarelto AG Rivals Too
January 5, 2023
-
TRENDS Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
-
REGULATORY PMDA Says “Slow Cartagena Review” Is Urban Legend, Set to Dispel Misconception
December 27, 2022
-
REGULATORY Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
-
BUSINESS Janssen Labor Union to Hold 1st Bargaining Session as Early as Jan. 11
December 23, 2022
-
REGULATORY Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
-
BUSINESS Janssen Japan Employees Form Labor Union to Counter Closing of Positions
December 21, 2022
-
BUSINESS Kissei Won’t Change 2025 Targets Despite Linzagolix Setback, Decide US Plan by March
December 20, 2022
-
BUSINESS Pharma Industry Mixed on Off-Year Drug Price Revision Plan for FY2023
December 19, 2022
-
REGULATORY Chuikyo OKs FY2023 Price Revision Outline Specifying “0.625 Times” Product Coverage Threshold
December 19, 2022
-
REGULATORY Ministers Agree on “4.375%” Product Coverage Line for 2023 “Off-Year” Drug Price Revision
December 16, 2022
-
REGULATORY Off-Year Re-Pricing Expected to Cover 70% of Listed Products; Special Steps for Unprofitable Drugs, Patented Meds
December 16, 2022
-
BUSINESS Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan: Exec
December 15, 2022
-
BUSINESS Total Sales of 25 Japan Drug Makers Up 12.9% in 1st Half, Global Players Fare Well While SMEs Falter
December 15, 2022
-
REGULATORY Japan to Refit R&D Tax Credit System to Boost Incentive; Lower Minimum Deduction Rate, Variable Cap
December 14, 2022
-
REGULATORY Japan Govt to Purchase Another 1 Million Courses of Xocova
December 14, 2022
-
COMMENTARY LDP Expects to Finalize Tax Reform Plan This Week; Will It Expand R&D Credit System?
December 13, 2022
-
REGULATORY 70% of Listed Meds Likely to Face Off-Year Re-Pricing If Prior Threshold Applied: MHLW
December 12, 2022
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…